NASDAQ: TEM · Technology · 10 alerts · CIK 1717115
Share price
$64.76Close, Nov 16
Sector
Technology
Industry
Services-Computer Programming, Data Processing, Etc.SIC 7370
Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Tempus AI, Inc. filings on SEC EDGAR ↗
Tempus AI Director David R. Epstein Sells $27.5K of Stock
David R. Epstein, Director, sold 370 shares of Tempus AI, Inc. at $74.29 a share, worth $27.5K in total on Nov 2, 2026. Shares held after the trade: 30,474 (-1.2%).
Tempus AI reported total net revenue of $411.5 million for the third quarter of 2026, a 23% increase year-over-year, driven by growth in both Diagnostics and Data and Applications segments. The company significantly narrowed its net loss to $14.9 million compared to $80.0 million in the prior year period, aided by a substantial $108.9 million gain on marketable equity securities.
Tempus AI reported record Q3 2026 revenue of $411.5 million, a 23% year-over-year increase driven by strong growth in its Oncology and Data & Applications segments. The company narrowed its net loss to $14.9 million and raised its full-year 2026 revenue guidance to a range of $1.60 billion to $1.605 billion.
Term
Q3 2026
“Q3 was another record quarter, as we delivered $411.5 million of revenue, led by accelerating unit growth of 32% in our oncology business and increasing momentum of 33% revenue growth in Data & Applications. These results reinforce the durability of our model as our best-in-class diagnostic platform enhances our data and AI offerings, distinguishes our business from our many competitors, and helps drive our performance quarter after quarter.”
Tempus AI CEO and Chairman Eric P. Lefkofsky Sells $17.6M of Stock
Eric P. Lefkofsky, CEO and Chairman, sold 250,000 shares of Tempus AI, Inc. at $67.36 to $72.31 a share (average $70.36) in 24 transactions, worth $17.6M in total on Oct 27, 2026. Shares held after the trade: 50,000 (-20.9%).
Tempus AI Licensing Deal with Bristol-Myers Squibb Company Worth $192M
Tempus AI entered into a series of agreements with Bristol-Myers Squibb (BMS) and Pathos AI to expand the use of its de-identified multimodal real-world data and analysis tools. The deal provides for aggregate cash payments to Tempus of $192.5 million over approximately five years, including $137.5 million for oncology data services to BMS and $55 million for neurology data and agentic tools to Pathos to support BMS's therapeutic development.